167 related articles for article (PubMed ID: 35672925)
1. PBRM1 deficiency oncogenic addiction is associated with activated AKT-mTOR signalling and aerobic glycolysis in clear cell renal cell carcinoma cells.
Tang Y; Jin YH; Li HL; Xin H; Chen JD; Li XY; Pan YF
J Cell Mol Med; 2022 Jul; 26(14):3837-3849. PubMed ID: 35672925
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
3. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway.
Liu G; Zhao X; Zhou J; Cheng X; Ye Z; Ji Z
Cell Physiol Biochem; 2018; 48(1):371-384. PubMed ID: 30016766
[TBL] [Abstract][Full Text] [Related]
4. Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma.
Schoenfeld DA; Zhou R; Zairis S; Su W; Steinbach N; Mathur D; Bansal A; Zachem AL; Tavarez B; Hasson D; Bernstein E; Rabadan R; Parsons R
Mol Cancer Res; 2022 Aug; 20(8):1193-1207. PubMed ID: 35412614
[TBL] [Abstract][Full Text] [Related]
5. ZNF471 Interacts with BANP to Reduce Tumour Malignancy by Inactivating PI3K/AKT/mTOR Signalling but is Frequently Silenced by Aberrant Promoter Methylation in Renal Cell Carcinoma.
Wang X; Yao L; Li Z; Zhang J; Ruan M; Mulati Y; Gan Y; Zhang Q
Int J Biol Sci; 2024; 20(2):643-663. PubMed ID: 38169650
[No Abstract] [Full Text] [Related]
6. PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma.
Chowdhury B; Porter EG; Stewart JC; Ferreira CR; Schipma MJ; Dykhuizen EC
PLoS One; 2016; 11(4):e0153718. PubMed ID: 27100670
[TBL] [Abstract][Full Text] [Related]
7. A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis.
Yang X; Cheng Y; Li P; Tao J; Deng X; Zhang X; Gu M; Lu Q; Yin C
Tumour Biol; 2015 Jan; 36(1):383-91. PubMed ID: 25266796
[TBL] [Abstract][Full Text] [Related]
8. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway.
Huang B; Ren J; Ma Q; Yang F; Pan X; Zhang Y; Liu Y; Wang C; Zhang D; Wei L; Ran L; Zhao H; Liang C; Wang X; Wang S; Li H; Ning H; Ran A; Li W; Wang Y; Xiao B
Mol Cancer; 2024 Feb; 23(1):34. PubMed ID: 38360682
[TBL] [Abstract][Full Text] [Related]
9. The platelet isoform of phosphofructokinase contributes to metabolic reprogramming and maintains cell proliferation in clear cell renal cell carcinoma.
Wang J; Zhang P; Zhong J; Tan M; Ge J; Tao L; Li Y; Zhu Y; Wu L; Qiu J; Tong X
Oncotarget; 2016 May; 7(19):27142-57. PubMed ID: 27049827
[TBL] [Abstract][Full Text] [Related]
10. LTB4R Promotes the Occurrence and Progression of Clear Cell Renal Cell Carcinoma (ccRCC) by Regulating the AKT/mTOR Signaling Pathway.
Zhang X; Wu H; Yan X; Ma J; Chen Z
Cells; 2022 Nov; 11(22):. PubMed ID: 36429034
[TBL] [Abstract][Full Text] [Related]
11. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
[TBL] [Abstract][Full Text] [Related]
12. LINC00941 promoted in vitro progression and glycolysis of laryngocarcinoma by upregulating PKM via activating the PI3K/AKT/mTOR signaling pathway.
Li Z; Jin Q; Sun Y
J Clin Lab Anal; 2022 Jul; 36(7):e24406. PubMed ID: 35588431
[TBL] [Abstract][Full Text] [Related]
13. METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression.
Liu Z; Sun T; Piao C; Zhang Z; Kong C
J Transl Med; 2021 May; 19(1):209. PubMed ID: 33985542
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.
Sun Q; Chen X; Ma J; Peng H; Wang F; Zha X; Wang Y; Jing Y; Yang H; Chen R; Chang L; Zhang Y; Goto J; Onda H; Chen T; Wang MR; Lu Y; You H; Kwiatkowski D; Zhang H
Proc Natl Acad Sci U S A; 2011 Mar; 108(10):4129-34. PubMed ID: 21325052
[TBL] [Abstract][Full Text] [Related]
16. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.
White NM; Masui O; Newsted D; Scorilas A; Romaschin AD; Bjarnason GA; Siu KW; Yousef GM
Br J Cancer; 2014 Mar; 110(5):1250-9. PubMed ID: 24496460
[TBL] [Abstract][Full Text] [Related]
17. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of KRT17 decreases osteosarcoma cell proliferation and the Warburg effect via the AKT/mTOR/HIF1α pathway.
Yan X; Yang C; Hu W; Chen T; Wang Q; Pan F; Qiu B; Tang B
Oncol Rep; 2020 Jul; 44(1):103-114. PubMed ID: 32627037
[TBL] [Abstract][Full Text] [Related]
19. HBXIP accelerates glycolysis and promotes cancer angiogenesis via AKT/mTOR pathway in bladder cancer.
Liu X; Li H; Che N; Zheng Y; Fan W; Li M; Li X; Xuan Y
Exp Mol Pathol; 2021 Aug; 121():104665. PubMed ID: 34216584
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men.
Ribback S; Cigliano A; Kroeger N; Pilo MG; Terracciano L; Burchardt M; Bannasch P; Calvisi DF; Dombrowski F
Oncotarget; 2015 May; 6(15):13036-48. PubMed ID: 25948777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
